|
gptkbp:instanceOf
|
gptkb:chemical_compound
antidepressant
serotonin–norepinephrine reuptake inhibitor
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:United_States
|
|
gptkbp:ATCCode
|
N06AX17
|
|
gptkbp:brand
|
gptkb:Savella
gptkb:Ixel
Toledomin
|
|
gptkbp:CASNumber
|
92623-85-3
|
|
gptkbp:compatibleWith
|
depression in United States
|
|
gptkbp:contraindication
|
uncontrolled narrow-angle glaucoma
concurrent MAOI use
|
|
gptkbp:developedBy
|
gptkb:Pierre_Fabre_Médicament
|
|
gptkbp:drugClass
|
SNRI
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C15H22N2O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Milnacipran
|
|
gptkbp:IUPACName
|
(±)-1-diethylamino-1-phenyl-2-(methylamino)propan-1-ol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibition
serotonin reuptake inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
246.35 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
insomnia
hyperhidrosis
|
|
gptkbp:synonym
|
gptkb:F_2207
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
fibromyalgia
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|